CRISPR Therapeutics AG Common Shares (CRSP) Technical Analysis
$48.75
Insights
- CRISPR Therapeutics AG is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for CRISPR Therapeutics AG stock suggests that it is a good time to buy
- Based on analysis of the Moving Averages technical indicator, CRISPR Therapeutics AG stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for CRISPR Therapeutics AG stock suggests that it is a good time to sell or bad time to initiate a fresh position
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 42.96 | Neutral |
Stochastic | 14.45, 8.61 | Buy |
Ultimate Oscillator | 44.68 | Neutral |
Stochastic Relative Strength Index | 2.83, 0.94 | Buy |
Moving Average Convergence Divergence | -0.01, 0.83 | Sell |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 55.97 | Buy |
20 | 55.03 | Buy |
50 | 53.24 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 54.07 | Sell |
20 | 54.42 | Buy |
50 | 53.71 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 56.25 | Sell |
20 | 55.34 | Sell |
50 | 53.52 | Sell |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 52.77 | Sell |
20 | 54.71 | Buy |
50 | 54.59 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 51.12 | Sell |
20 | 54.01 | Sell |
50 | 55.21 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 52.87 |
Resistance L2 | 51.93 |
Resistance L1 | 51.2 |
Pivot Point | 50.26 |
Support L1 | 49.53 |
Support L2 | 48.59 |
Support L3 | 47.86 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.